These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Controlling AAV Tropism in the Nervous System with Natural and Engineered Capsids. Castle MJ; Turunen HT; Vandenberghe LH; Wolfe JH Methods Mol Biol; 2016; 1382():133-49. PubMed ID: 26611584 [TBL] [Abstract][Full Text] [Related]
23. Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors. Shi W; Arnold GS; Bartlett JS Hum Gene Ther; 2001 Sep; 12(14):1697-711. PubMed ID: 11560765 [TBL] [Abstract][Full Text] [Related]
24. Programmable Assembly of Adeno-Associated Virus-Antibody Composites for Receptor-Mediated Gene Delivery. Zdechlik AC; He Y; Aird EJ; Gordon WR; Schmidt D Bioconjug Chem; 2020 Apr; 31(4):1093-1106. PubMed ID: 31809024 [TBL] [Abstract][Full Text] [Related]
25. Novel caprine adeno-associated virus (AAV) capsid (AAV-Go.1) is closely related to the primate AAV-5 and has unique tropism and neutralization properties. Arbetman AE; Lochrie M; Zhou S; Wellman J; Scallan C; Doroudchi MM; Randlev B; Patarroyo-White S; Liu T; Smith P; Lehmkuhl H; Hobbs LA; Pierce GF; Colosi P J Virol; 2005 Dec; 79(24):15238-45. PubMed ID: 16306595 [TBL] [Abstract][Full Text] [Related]
26. Context-Specific Function of the Engineered Peptide Domain of PHP.B. Martino RA; Fluck EC; Murphy J; Wang Q; Hoff H; Pumroy RA; Lee CY; Sims JJ; Roy S; Moiseenkova-Bell VY; Wilson JM J Virol; 2021 Sep; 95(20):e0116421. PubMed ID: 34346767 [TBL] [Abstract][Full Text] [Related]
31. Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection. Wobus CE; Hügle-Dörr B; Girod A; Petersen G; Hallek M; Kleinschmidt JA J Virol; 2000 Oct; 74(19):9281-93. PubMed ID: 10982375 [TBL] [Abstract][Full Text] [Related]
32. Chemical Modifications of the Capsid for Redirecting and Improving the Efficacy of Adeno-Associated Virus Vectors. Lam AK; Frabutt D; Li L; Xiao W Hum Gene Ther; 2021 Dec; 32(23-24):1433-1438. PubMed ID: 34254844 [TBL] [Abstract][Full Text] [Related]
33. Improved Genome Packaging Efficiency of Adeno-associated Virus Vectors Using Rep Hybrids. Mietzsch M; Eddington C; Jose A; Hsi J; Chipman P; Henley T; Choudhry M; McKenna R; Agbandje-McKenna M J Virol; 2021 Sep; 95(19):e0077321. PubMed ID: 34287038 [TBL] [Abstract][Full Text] [Related]
34. Characterizing Glycosylation of Adeno-Associated Virus Serotype 9 Capsid Proteins Generated from HEK293 Cells through Glycopeptide Mapping and Released Glycan Analysis. Zhou Y; Priya S; Ong JY Microorganisms; 2024 May; 12(5):. PubMed ID: 38792776 [TBL] [Abstract][Full Text] [Related]
36. Engineering the AAV capsid to evade immune responses. Barnes C; Scheideler O; Schaffer D Curr Opin Biotechnol; 2019 Dec; 60():99-103. PubMed ID: 30807882 [TBL] [Abstract][Full Text] [Related]
37. Nuclear translocation of adeno-associated virus type 2 capsid proteins for virion assembly. Popa-Wagner R; Sonntag F; Schmidt K; King J; Kleinschmidt JA J Gen Virol; 2012 Sep; 93(Pt 9):1887-1898. PubMed ID: 22694902 [TBL] [Abstract][Full Text] [Related]
38. The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity. Girod A; Wobus CE; Zádori Z; Ried M; Leike K; Tijssen P; Kleinschmidt JA; Hallek M J Gen Virol; 2002 May; 83(Pt 5):973-978. PubMed ID: 11961250 [TBL] [Abstract][Full Text] [Related]
39. Mapping an Adeno-associated Virus 9-Specific Neutralizing Epitope To Develop Next-Generation Gene Delivery Vectors. Giles AR; Govindasamy L; Somanathan S; Wilson JM J Virol; 2018 Oct; 92(20):. PubMed ID: 30089698 [TBL] [Abstract][Full Text] [Related]